Carboplatin During Craniospinal Radiotherapy for Children With Group 3 Medulloblastoma-A New Standard of Care?-Reply

Affiliations

¹ Cancer and Blood Disorders Center, Seattle Children's, Fred Hutchinson Cancer Research Center, University of Washington, Seattle.
² Department of Biostatistics, St Jude Children's Research Hospital, Memphis, Tennessee.

Comment

Sarah E S Leary et al. JAMA Oncol. 2022.

. 2022 Feb 1;8(2):302-303.

doi: 10.1001/jamaoncol.2021.6526.

¹ Cancer and Blood Disorders Center, Seattle Children's, Fred Hutchinson Cancer Research Center, University of Washington, Seattle.
² Department of Biostatistics, St Jude Children's Research Hospital, Memphis, Tennessee.

No abstract available

Comment on

Efficacy of Carboplatin and Isotretinoin in Children With High-risk Medulloblastoma: A Randomized Clinical Trial From the Children's Oncology Group.
Leary SES, Packer RJ, Li Y, Billups CA, Smith KS, Jaju A, Heier L, Burger P, Walsh K, Han Y, Embry L, Hadley J, Kumar R, Michalski J, Hwang E, Gajjar A, Pollack IF, Fouladi M, Northcott PA, Olson JM. Leary SES, et al. JAMA Oncol. 2021 Sep 1;7(9):1313-1321. doi: 10.1001/jamaoncol.2021.2224. JAMA Oncol. 2021. PMID: 34292305 Free PMC article. Clinical Trial.
Carboplatin During Craniospinal Radiotherapy for Children With Group 3 Medulloblastoma-A New Standard of Care?
Karajannis MA, Mauguen A, Kramer K. Karajannis MA, et al. JAMA Oncol. 2022 Feb 1;8(2):301-302. doi: 10.1001/jamaoncol.2021.6523. JAMA Oncol. 2022. PMID: 34882185 No abstract available.